Abstract
The apolipoprotein B mRNA-editing enzyme catalytic polypeptide (APOBEC) family of cytidine deaminases has emerged as an intensively studied field as a result of their important biological functions. These enzymes are involved in lipid metabolism, antibody diversification, and the inhibition of retrotransposons, retroviruses, and some DNA viruses. The APOBEC proteins function in these roles by deaminating single-stranded (ss) DNA or RNA. There are two high-resolution crystal structures available for the APOBEC family, Apo2 and the C-terminal catalytic domain (CD2) of Apo3G or Apo3G-CD2 [Holden et al. (Nature 456:121–124, 2008); Prochnow et al. (Nature 445:447–451, 2007)]. Additionally, the structure of Apo3G-CD2 has also been determined using NMR [Chen et al. (Nature 452:116–119, 2008); Furukawa et al. (EMBO J 28:440–451, 2009); Harjes et al. (J Mol Biol, 2009)]. A detailed structural analysis of the APOBEC proteins and a comparison to other zinc-coordinating deaminases can facilitate our understanding of how APOBEC proteins bind nucleic acids, recognize substrates, and form oligomers. Here, we review the recent development of structural and functional studies that apply to Apo3G as well as the APOBEC deaminase family.
Similar content being viewed by others
References
Holden LG, Prochnow C, Chang PY, Bransteitter R, Chelico L, Sen U, Stevens RC, Goodman MF, Chen XS (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:121–124
Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445:447–451
Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:116–119
Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, Hayashi F, Kobayashi N, Yokoyama S, Takaku H, Katahira M (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J 28:440–451
Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, Nowarski R, Gross JD, Kotler M, Harris RS, Matsuo H (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (in press)
Jarmuz A, Clhester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285–296
Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374–386
Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15:166–170
Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80:5992–6002
Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14:1385–1391
Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho S, Malim MH (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14:1392–1396
Bogerd HP, Wiegand HL, Doehle BP, Cullen BR (2007) The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364:486–493
Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, Giannoni F, Teng B, Davidson NO, Scott J (1993) The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 28:20709–20712
Teng B, Burant CF, Davidson NO (1993) Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260:1816–1819
Chester A, Scott J, Anant S, Navaratnam N (2000) RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta 1494:1–13
Petersen-Mahrt SK, Neuberger MS (2003) In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J Biol Chem 278:19583–19586
Mehta A, Kinter MT, Sherman NE, Driscoll DM (2000) Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 20:1846–1854
Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–563
Neuberger MS, Harris RS, Di Noia JM, Petersen-Mahrt SK (2003) Immunity through DNA deamination. Trends Biochem Sci 28:305–312
Bransteitter R, Pham P, Scharff MD, Goodman MF (2003) Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 100:4102–4107
Langlois MA, Beale RCL, Conticello SG, Neuberger MS (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases providing insight into their DNA target site specificities. Nucleic Acids Res 33:1913–1923
Pham P, Bransteitter R, Petruska J, Goodman MF (2003) Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424:103–107
Peters A, Storb U (1996) Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 4:57–65
Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, Yel L, Forveille M, Kavli B, Krokan HE, Ochs HD, Fischer A, Durandy A (2003) Human uracil–DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 4:1023–1028
Schrader CE, Guikema JE, Wu X, Stavnezer J (2009) The roles of APE1, APE2, DNA polymerase beta and mismatch repair in creating S region DNA breaks during antibody class switch. Philos Trans R Soc Lond B 364:645–652
Revy P, Muto T, Levy Y, Greissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A (2000) Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102:565–575
Durandy A, Peron S, Fischer A (2006) Hyper-IgM syndromes. Curr Opin Rheumatol 18:369–376
Minegishi Y, Lavoie A, Cunningham-Rundles C, Bedard P, Hebert J, Cote L, Dan K, Sedlak D, Buckley RH, Fischer A, Durandy A, Conley ME (2000) Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 97:203–210
Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646–650
Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13:2009–2013
Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398–1403
Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404–1407
Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591–601
Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif–Cul5–SCF complex. Science 302:1056–1060
Opi S, Kao S, Goila-Gaur R, Khan M, Miyagi E, Takeuchi H, Strebel K (2007) Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 81:8236–8246
Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the nc basic linker. J Virol 81:5000–5013
Alce TM, Popik W (2004) APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 279:34083–34086
Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L (2004) The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 279:33177–33184
Luo K, Lui B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF (2004) Amino-terminal region of the human immunodeficiency virus type 1 nucleo-capsid is required for human APOBEC3G packaging. J Virol 78:11841–11852
Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K (2005) Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 79:5870–5874
Zennou VD, Perez-Caballero D, Gottlinger H, Bieniasz PD (2004) APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 78:12058–12061
Scharfer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163–168
Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113:803–809
Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99–103
Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21–31
Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94–98
Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11:435–442
Suspene R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32:2421–2429
Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit effects in plus-strand DNA transfer and integration. J Virol 81:7099–7110
Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu X (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol 81:7238–7248
Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4:e1000231. doi:10.1371/journal.ppat.1000231
Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282:2587–2595
Iwatani Y, Chan DSB, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35:7096–7108
Guo F, Cen S, Niu M, Saadatmand J, Kleiman L (2006) Inhibition of tRNAlys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 80:11710–11720
Li XY, Guo F, Zhang L, Kleiman L, Cen S (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem 282:32065–32074
Gooch BD, Cullen BR (2008) Functional domain organization of human APOBEC3G. Virology 379:118–124
Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5:e1000330
Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81:13346–13353
Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol 82:2652–2660
Doehle BP, Schafer A, Cullen BR (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339:281–288
Bourara K, Liegler TJ, Grant RM (2007) Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog 3:1477–1485
Dang Y, Wang X, Esselman WJ, Zheng YH (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80:10522–10533
Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K (2005) G to A hypermutation of hepatitis B virus. Hepatology 41:626–633
Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizacker F (2005) APOBEC-mediated interference with hepadnavirus production. Hepatology 42:309–310
Kock J, Blum HE (2008) Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 89:1184–1191
Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 102:8321–8326
Turelli P, Mangeat B, Jost S, Vianin S, Trono D (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829
Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16:480–485
Vartanian J, Guetard D, Henry M, Wain-Hobson S (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320:230–233
Chiu YL, Greene WC (2009) APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci 364:689–703
Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T (2003) Constitutive expression of AID leads to tumorigenesis. J Exp Med 197:1173–1181
Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T (2007) Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer 120:469–476
Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T (2008) Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47:888–896
Longerich S, Orelli BJ, Martin RW, Bishop DK, Storb U (2008) Brca1 in immunoglobulin gene conversion and somatic hypermutation. DNA Repair (Amst) 7:253–266
Marusawa H (2008) Aberrant AID expression and human cancer development. Int J Biochem Cell Biol 40:1399–1402
Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T (2007) Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13:470–476
Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, Chiba T (2008) Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer 123:2735–2740
Conticello SG, Langlois MA, Yang Z, Neuberger MS (2007) DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 94:37–73
Betts L, Xiang S, Short SA, Wolfenden R, Carter CW (1994) Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex. Curr Biol 235:635–656
Navaratnam N, Fujino T, Bayliss J, Jarmuz A, How A, Richardson N, Somasekaram A, Bhattacharya S, Carter C, Scott J (1998) Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J Mol Biol 275:695–714
Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 19:207–216
Teh AH, Kimura M, Yamamoto M, Tanaka N, Yamaguchi I, Kumasaka T (2006) The 1.48 Å resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry (Mosc) 45(782):5–7833
Chung SJ, Fromme JC, Verdine GL (2005) Structure of human cytidine deaminase bound to a potent inhibitor. J Med Chem 48:658–660
Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34:4677–4684
Chelico L, Pham P, Calabrese P, Goodman MF (2006) APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat Struct Mol Biol 13:392–399
Chelico L, Goodman MF (2008) A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem 283:13780–13791
Chelico L, Pham P, Goodman MF (2009) Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat Struct Mol Biol 16:454–455; author reply 455–456
Nowarski R, Britan-Rosich E, Shiloach T, Kotler M (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15:1059–1066
Rausch JW, Chelico L, Goodman MF, Le Grice SF (2009) Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem 284:7047–7058
Conticello SG, Langlois MA, Neuberger MS (2007) Insights into DNA deaminases. Nat Struct Mol Biol 14:7–9
Losey HC, Ruthenburg AJ, Verdine GL (2006) Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat Struct Mol Biol 13:153–159
Basu U, Franklin A, Alt FW (2009) Post-translational regulation of activation-induced cytidine deaminase. Philos Trans R Soc Lond B 364:667–673
Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, Telenti A, Michielin O (2007) Model structure of human APOBEC3G. PLoS ONE 2:e378
Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid difference in the host APBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101:3770–3774
Mangeat B, Turelli P, Liao S, Trono D (2004) a single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 15:14481–14483
Schrofelbauer B, Chen D, Landau NR (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101:3927–3932
Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J Virol 81:3807–3815
Zhang L, Saddatmand J, Li X, Guo F, Niu M, Jiang J, Kleiman L, Cen S (2007) Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370:113–121
Simon V, Zennou VD, Murray D, Huang Y, Ho DD, Bieniasz PD (2005) Natrual variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1:e6
Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80:3112–3115
Liu B, Sarkis PT, Luo K, Yu Y, Yu XF (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79:9579–9587
Russell RA, Pathak VK (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81:8201–8210
Marin M, Golem S, Rose KM, Kozak SL, Kabat D (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol 82:987–998
Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC (2006) Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular ribonucleoprotein particles from dimeric subunits. J Biol Chem 281:38122–38126
Bennett RP, Salter JD, Liu X, Wedekind JE, Smith HC (2008) APOBEC3G subunits self-associate via the C-terminal deaminase domain. J Biol Chem 283:33329–33336
Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195–201
DeLano WL (2002) The PyMOL molecular graphics system. DeLano, San Carlos
Acknowledgment
This work was supported by the National Institutes of Health grant R01GM087986.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bransteitter, R., Prochnow, C. & Chen, X.S. The current structural and functional understanding of APOBEC deaminases. Cell. Mol. Life Sci. 66, 3137–3147 (2009). https://doi.org/10.1007/s00018-009-0070-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-009-0070-y